Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
Gynecol Oncol Rep
.
2020 Sep 17:34:100648.
doi: 10.1016/j.gore.2020.100648.
eCollection 2020 Nov.
Authors
Johnathan Oh
1
,
Minal Barve
1
2
,
Neil Senzer
3
,
Phylicia Aaron
3
,
Luisa Manning
3
,
Gladice Wallraven
3
,
Ernest Bognar
3
,
Laura Stanbery
3
,
Staci Horvath
3
,
Meghan Manley
3
,
John Nemunaitis
3
,
Adam Walter
4
,
Rodney P Rocconi
5
Affiliations
1
Texas Oncology, P.A., Dallas, TX, United States.
2
Mary Crowley Cancer Research Centers, Dallas, TX, United States.
3
Gradalis, Inc., Carrolton, TX, United States.
4
ProMedica, Toledo, OH, United States.
5
University of South Alabama - Mitchell Cancer Institute, Mobile, AL, United States.
PMID:
33364285
PMCID:
PMC7752749
DOI:
10.1016/j.gore.2020.100648
No abstract available